Abstract library

1909 results for "digestive endocrine tumors".
#11 Plasma chromogranin - A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Sara Massironi
#219 Predictive Factors of Tumor Control in Patients with Well-differentiated Digestive Endocrine Carcinomas (WDEC) Treated with Lanreotide
Introduction: Somatostatin analogues (SSA) are indicated in the control of secretory symptoms of digestive endocrine tumors. The antiproliferative effect of SSA was recently demonstrated (Rinke et al, JCO 2009).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Philippe Ruszniewski
#1675 Abdominal Obesity, Fasting Glucose and Metabolic Syndrome Are Risk Factors for Well Differentiated Digestive Neuroendocrine Tumors
Introduction: Digestive NETs(DNETs)`s incidence has increased last 40 years. Visceral obesity and metabolic syndrome (MetSyn) were recently reported to be associated with several cancers, although not so far with DNET.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr. Ana Paula Santos
#113 Prolonged cell survival in xenografts from human digestive endocrine tumors
Introduction: Gastroenteropancreatic endocrine tumors have the capacity to achieve very large tumor masses despite usually very low proliferative rates. This suggests that neoplastic endocrine cells may have long life spans, implying the development of specific mechanisms able to promote cell survival.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Colette Roche
#1124 Correlation Between the 18F-FDG Uptake and Pathological Data in Well-Differentiated Digestive and Pulmonary Neuroendocrine Tumors (NET)
Introduction: The 18F-FDG uptake assessed by PET/CT is correlated to prognosis in most tumors.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Margot Bucau
#83 Surgical treatment of duodenopancreatic neuroendocrine tumors (pNETs) in patients with multiple endocrine neoplasia type 1 (MEN 1): a Dutch consensus statement
Introduction: Duodenopancreatic neuroendocrine tumors (pNETs) in multiple endocrine neoplasia type 1 (MEN 1) are the most important cause of MEN 1-related death. Surgery is the only curative treatment, but controversy exists on the optimal strategy. Recent guidelines on pNETs have limited recommendations specific for MEN 1. Therefore, a Dutch multidisciplinary consensus meeting was organized.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Carolina RC Pieterman
#18 Long-acting release octreotide induce complete response in type 1 gastric carcinoid tumors
Introduction: Gastric endocrine tumors (GET) are increasingly recognized due to expanding indications of upper gastrointestinal endoscopy. Often silent and benign, GET may also be aggressive when sporadic and may sometimes mimic the course of gastric adenocarcinoma. Current incidence of GETs is estimated at around 8% of digestive endocrine tumors. Yearly age-adjusted incidence is around 0.2 per population of 100,000. Gastric carcinoids (ECLomas) develop from gastric enterochromaffin-like cells (ECL cells) in response to chronically elevated gastrin. Type 1 tumors (ECLomas in the course of atrophic gastritis) may occur in conditions of achlorhydria secondary to auto-immune atrophic fundic gastritis. It occurs mostly in women and they are non-functioning tumors, typically found during upper GI endoscopy performed for dyspepsia. ECLomas present frequently as multiple polyps, usually < 1 cm in diameter in the gastric fundus. Type 1 tumors are almost exclusively benign lesions with little risk of deep invasion of the gastric parietal wall. The neoplastic ECL cells become progressively dedifferentiated with an increasing number of Ki-67 immunoreactive (IR) cell nuclei. In addition, there is a substantial decrease in argynophil and IR NE cells that can be visualized by conventional methods. ECLomas secondary to hypergastrinemia should be closely followed for signs of clinical and histopathological tumor progression. Such ECLomas deserve early, active, radical surgical treatment.
Traditionally, gastric carcinoid type 1 (GCA1s) are endoscopically or surgically removed, depending on the number, appearance and size of the tumors. Antrectomy, with surgical excision of the majority of the G cells, is thought to facilitate regression of these tumors by removing the source of excessive gastrin secretion; however, the long-term benefits of antrectomy still remain uncertain. Although proton pump inhibitors are effective in reducing hypergastrinemia-induced gastric acid hypersecretion in GCA2, they do not affect ECL-cell hyperplasia, and therefore their role in GCA1 is limited. Moreover, in selected cases, significant reduction of hypergastrinemia does not prevent development of ECL carcinoid, suggesting that, in addition to hypergastrinemia, other pathogenic or genetic factors may be involved. Treatment with somatostatin analogues (SSA) might impede ECL-cell hyperplasia by suppressing gastrin secretion and/or by a direct anti-proliferative effect on ECL cells. Treatment with SSAs in GCA1 leads to a substantial tumor load reduction, with a concomitant decrease of serum gastrin levels. Published data indicate an important anti-proliferative effect of SSA on ECL cells, providing clinical benefit and obviating, at least temporarily, the need for invasive therapies for GCA1. Morphometric studies demonstrated that, while antrectomy specifically decreased the volume of ECL cells versus the total volume of endocrine cells, octreotide reduces the overall endocrine cell volume. Although the number of treated patients is small, it has been suggested that SSA may exert important anti-proliferative effects either directly, by inhibiting ECL-cells proliferation, or indirectly through suppression of gastrin hypersecretion.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Ricardo Caponero
#126 Assessment of the proliferation marker Ki-67 by endoscopic ultrasound guided-Fine Needle Aspiration (EUS-FNA) in pancreatic endocrine tumors: A comparative analysis with histology of the surgical specimen
Introduction: Assessment of the proliferative index by Ki-67 immuno-labelling is an important prognostic parameter for the biologic behavior of digestive neuroendocrine tumors, usually established on the histological specimen obtained after surgery or macro-biopsy. However, small pancreatic endocrine tumors (PET) are more and more often recognized by CT/MRI and diagnosed by EUS. The value of Ki-67 labelling index (Ki-67-LI) on fine needle aspiration (FNA) is not well-established in this setting, although regularly assessed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Ivan Borbath
#1387 FOLFOX in Neuroendocrine Tumors
Introduction: Favorable toxicity profile and significant antitumor activity of FU-oxaliplatin in several malignancies led us to evaluate FOLFOX in advanced neuroendocrine carcinomas (NETs).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Marjorie Faure
Authors: Faure M, Raoul J L, Autret A, Mineur L, ...
#186 Occurrence of Other Primary Malignancies in Patients with Endocrine Tumors of the Digestive Tract and Pancreas
Introduction: Endocrine tumors of the digestive tract and pancreas (GEP-NET) are often considered to be associated with other primary malignancies.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Kimberly Kamp